Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Enhanced Psilocybin Microdosing for Trauma in Chronic Illness
NCT05042466Phase 1Unknown
- Sponsor
- NWTraumatherapies
- Start
- Sep 2023
- Primary completion
- Aug 2025
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of psilocybin in post-traumatic stress disorder (PTSD), major depressive disorder (MDD), somatic symptom disorder (SSD) and 1 more, sponsored by NWTraumatherapies. Primary endpoints: Global Assessment of Functioning at 8 weeks and Brief Addiction Monitor at 8 weeks. Status: unknown.
02
Drugs
psilocybin
03
Conditions
post-traumatic stress disorder (PTSD)major depressive disorder (MDD)somatic symptom disorder (SSD)psychological trauma
Beyond the preview
Go deeper on NCT05042466.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05042466.